We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Roche Halts Taspoglutide Dosing Due to Hypersensitivity Issues
Roche Halts Taspoglutide Dosing Due to Hypersensitivity Issues
September 15, 2010
Roche is halting dosing in Phase III trials of its diabetes drug taspoglutide after higher-than-expected discontinuations due to gastrointestinal tolerability and hypersensitivity reactions.